

Attention Deficit Hyperactivity Disorder

Dr Daryl Efron

Attention Deficit Hyperactivity Disorder

- History
- Definition
- Neurobiology
- Causes
- Assessment
- Comorbidities
- Management
 - (non-pharm), meds
- Developmental trajectories

1798 Sir Alexander Crichton



AN INQUIRY
INTO THE
NATURE AND ORIGIN
OF
MENTAL DERANGEMENT.
COMPREHENDING
A CONCISE SYSTEM
OF THE
PHYSIOLOGY AND PATHOLOGY
OF THE
HUMAN MIND.
AND A
HISTORY OF THE PASSIONS AND THEIR EFFECTS.

BY ALEXANDER CRICHTON, M.D.
PHYSICIAN TO THE WESTMINSTER HOSPITAL, AND PUBLIC
LECTURER ON THE THEORY AND PRACTICE OF
PHYSIC, AND ON CHEMISTRY.

VOLUME I.

LONDON:
PRINTED FOR T. CADELL, JUNIOR, AND W. DAVIES,
IN THE STRAND.
1798.

*“a history of the passions
and their effects”*

Mental restlessness:

- Deficits in attention
- Occurring across situations (e.g. home & school)
- Begins early in life
- Causes impairment in learning

1865


Dr Heinrich Hoffmann



Let me see if Philip can
Be a little gentleman;
Let me see if he is able
To sit still for once at table:"
Thus Papa bade Phil
behave;
And Mamma looked very
grave.

**But fidgety Phil,
He won't sit still;
He wriggles,
And giggles,
And then, I declare,
Swings backwards and
forwards,
And tilts up his chair,
Just like any rocking-horse-
"Philip! I am getting cross!"**

1902 Sir George Still



- RCP lectures
- 43 children
 - inattentive, impulsive, defiant and overly emotional
 - *“defective moral conduct”*



History

1920's-30's Post-encephalitic behaviour disorder

(Spanish flu pandemic 1917-28)

1937 Charles Bradley - benzedrine

1950's Minimal brain damage

1954 Ritalin (Ciba-Geigy)

- Leandro Panizzon, wife Margeurite ("Rita")

1960's Minimal brain dysfunction

1960's-70's Hyperactivity

1980's Attention deficit disorder (Douglas 1972)

- 1980 DSM-III

1994 DSM-IV: ADHD

Definition

Developmentally inappropriate degrees of:

- impulsivity,
- inattention,
- and often hyperactivity

ADHD: DSM-IV criteria (1994)

Developmentally inappropriate degrees of:

- inattention,


Often has difficulty sustaining attention in tasks or play activities
Often does not follow through on instructions and fails to finish schoolwork chores or duties in the workplace

- impulsivity,
- and often hyperactivity

Often interrupts or intrudes on others
Often leaves seat in classroom

ADHD - DSM-IV criteria (1994)

- Symptoms present > 6 months
- Onset before age 7
- Clear evidence impairment in ≥ 2 settings
 - in social, academic or occupational functioning
- Excl PDD, psychotic disorder, personality disorder



Subtypes

	Inattention ($\geq 6/9$)	Hyperactive / Impulsive ($\geq 6/9$)
Combined type (75%)	✓	✓
Predominantly Inattentive (25%)	✓	
Predominantly Hyperactive / Impulsive		✓



Inattentive type

Different to combined type

- symptoms (not disruptive)
- age of onset
- gender ratios
- assoc problems - language / learning, social skills deficits, anxiety
- response to stimulants less marked

Problems with DSM-IV

- Thresholds arbitrary (eg. >6 inatt, 4-5 H-I)
- Inattentives included in “Disruptive Behaviour Disorders”
- No variation by developmental stage
 - item content, thresholds
- Definition of impairment?
- How to combine reports from different informants?

ADHD: DSM-5 criteria (May 2013)


1. Onset before age 12 (during childhood)
2. Adults (age > 17 yrs)
 - fewer symptoms required
 - 5/9 from either / both lists
 - alternative item wording
 - feels restless
 - fails to meet deadlines, difficulty completing forms / paying bills
 - loses keys, mobile phone
 - makes important decisions on spur of moment
 - commits to relationship after brief acquaintance
3. PDD exclusion removed

DSM-5: descriptive text

- “Signs may be minimal or absent when the individual is ...in a novel setting, is engaged in especially interesting activities, has consistent external stimulation (e.g. via electronic screens), or is interacting in one-on-one situations (e.g. the clinician’s office).”
- Comorbidities
 - “Assoc features may include delayed language or social development, irritability / mood lability, learning disorders”
- Different informants
 - “Confirmation of substantial symptoms across settings requires consulting informants who have seen the individual in those settings”

Epidemiology

(Polanczyk et al. *Am J Psychiatry* 2007)



Aust 6.8% (*Graetz JAACAP* 2001)

Prevalence

- Estimates vary: 2-18% (3-5%)
- All countries, all ethnic groups
- Uneven socio-economic distributions
- Males
 - 5-10X in clinic referrals
 - 2-3X in community settings
- Mean age at diagnosis 9 yrs (boys < girls)

Effects

Individual

- Reduced quality of life (*Klassen 2004, Sciberras 2011*)
- Underachievement (*Hinshaw 1992*)
- Social isolation (*Friedman 2003*)

Flow-on effects

- Family stress (*Johnston & Mash 2001, Cussen 2011*)
- Impact on schools, workplaces, broader community

Costs

\$US31-52 billion / yr!

- health care, lost productivity, criminality etc

“A serious public health problem” CDC 2002



Attention

Alerting

- Initial arousal to sensory stimuli (warning signal)

Orienting

- Attend quickly to source

* Executive

- Choices – shifting, switching
- Effortful control (non-habitual)
- Unique to humans

Neuropsychology

(Rappley NEJM 2005)

Response inhibition (self-regulation)

- Consciously inhibit immediately rewarding response
- Allocation of attention (will-power)

Working memory (temp file)

- auditory, visuo-spatial

Executive function deficits

(Douglas 1970; Schachar 2012)

- Planning, preparing, initiating (Tower of Hanoi)
- Holding (WM – verbal, visuoaspatial)
- Switching (mental flexibility eg. Wisconsin card sorting test)
- Error processing – identification, adjustment
- Inhibitory control
 - withholding (Go-no go, CPT)
 - cancelling (braking eg. Stop signal task)

Executive function deficits in ADHD

- Seen in all subtypes
- Variable between subjects
- Weak relationship with functional deficits
- Insufficient sensitivity and specificity for diagnostic purposes
- Lacks utility to predict course / outcomes

Neurophysiology



- Dopamine dysregulation (receptor / concentration) (*Sagvolden 2005*)
 - Mesolimbic – delay aversion, impulsivity, disinhibition
 - Mesocortical – inattention, poor planning
 - Nigrostriatal – neurological “soft signs”, clumsiness
- Disordered activation (fMRI)
 - under activation
 - activate more diffuse areas than controls during tasks
- Reduced “functional connectivity” (steady state) (*Sun 2012*)

Structural imaging

- MRI - total cerebral volume and cerebellar vol. 3% reduced cf controls (*Castellanos JAMA 2002*)
 - Reduced cortical thickness
 - Caudate vol smaller school-age, no diff older
 - Holds when control for med history
- Delayed cortical thickening, gyrification (*Shaw 2012*)
 - Normalization - remission / lack - persistence (*Halperin 2011*)
- Adults with ADHD – cortical thinning in DLPFC, R inf parietal lobe (*Makris 2007*)

Brain structures involved

(Castellanos & Tannock Nature 2002)




Limbic System (amygdala, hippocampus, anterior cingulate)

Deep grey matter
(caudate, putamen)

Cerebellum

Co-morbidities

- 80% have one or more
- Often dictate priority interventions
- Assoc with different trajectories
 - Aggression – conduct disorder, antisocial PD
 - Anxiety - depression



...And his dad's never there
and he watches a lot of
telly and eats junk food...

All of which can
be fixed with
medication.



Aetiology - Genetics

(Hay & Levy 2002, Faraone 2005; ADHD Molecular Genetics Network)

- Heritability > 70%
 - 1st degree relatives - 4-8 X increased risk
 - MZ twins >50% concordance; sibs 33%
- Linkage studies
 - Neurotransmitters with candidate polymorphisms: dopamine (DRD4, DAT1), NA, MAO, GABA, serotonin – inconsistent / unreplicated findings
- Genome-wide scan (GWAS)
 - Hypothesis-free – need v large samples (cross-disorder now)
 - No genome wide associations (Neale et al meta-analysis JAACAP 2010)

Many genes of small effect (OR for any one ~ 1.2)

Aetiology - Genetics

(*Williams et al, Lancet 2010*)

Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis



Nigel M Williams, Irina Zaharieva, Andrew Martin, Kate Langley, Kiran Mantripragada, Ragnheidur Fosdøl, Hreinn Stefansson, Kari Stefansson, Pall Magnússon, Ólafur Ó Guðmundsson, Ómar Guðafsson, Peter Holmans, Michael J Owen, Michael O'Donovan, Anita Thapar

Summary

Background Large, rare chromosomal deletions and duplications known as copy number variants (CNVs) have been implicated in neurodevelopmental disorders similar to attention-deficit hyperactivity disorder (ADHD). We aimed to establish whether burden of CNVs was increased in ADHD, and to investigate whether identified CNVs were enriched for loci previously identified in autism and schizophrenia.

Lancet 2010; 376: 1401-08

Published Online

September 30, 2010

DOI:10.1016/S0140-

6736(10)61109-9

SNP microarray (n=410 cases, controls 1156)

- copy no. variants (deletions, duplications) burden incr. 2.1
- **loci signals overlap with autism, ID, SCZ, epilepsy (multifinality)**

Aetiology - Environmental exposures




Toxins

- embryopathic
 - tobacco (*Thapar 2003*)
 - alcohol (FASD) (*Talge 2007, Peadon 2010*)
- Childhood neurotoxins
 - lead (*Goodlad 2013*)



Diet (food sensitivities)

- colourings, preservatives
- salicylates, amines




Biological risk factors

- Premature birth (*van Baar 2009, Lindstrom 2011*), low birth weight (OR 2- 2.5) (*Galera 2011*)
 - decr grey matter, white matter injuries
 - disruption of cortical development / connectivity
 - contribution of sensory stress, sleep deprivation, repetitive pain, disrupted parent-child interaction?
- Brain injury
 - traumatic (*Herskivitz 1999*), CVA - putamen (*Max 2002*), infective

Parenting / family

- Family dysfunction, parental stress
 - common in ADHD (*Johnson & Mash 2001*)
- Parental psychopathology, family conflict more strongly assoc with ODD / CD than ADHD (*Deault 2010*)
- ADHD predicted by
 - Post-natal depression (*Sciberras 2011*)
 - Early deprivation (*Kreppner 2001*)
 - Psychosocial disadvantage (*Biederman 1995*)
 - Harsh / coercive parenting of young children (*Hughes & Ensor 2007*)
- Early maternal “scaffolding behaviour” (supportive, assisting risk-taking / growth) protects against ADHD in children with dev delays (*Baker 2010*)



Hamer Science, 2002



Genetics – environment

(Wilcutt et al 2010)

Critical periods

- Brain vulnerability / expression varies depending on developmental stage of insult
eg. embryotoxins, attachment, binocular vision / amblyopia

Interaction effects

- polymorphism plus exposure → ↑ risk
eg. DAT-3 / smoking in utero *(Kahn 2003)*

Epigenetics

- inherited changes in phenotype caused by variation in gene expression (chromatin remodelling, DNA methylation)

Polygenic disorders

– pathway analysis *(Neale 2009)*

PHENOTYPE	behavioural traits
PHYSIOLOGY	functional connectivity, activation
STRUCTURE	
EPIGENETICS	Environmental influences
GENETICS	SNPs, microdeletions / microduplications,




Polygenic disorders

– pathway analysis *(Neale 2009)*

PHENOTYPE	behavioural traits
COGNITIVE ENDO-PHENOTYPE	executive functions (developmental skills)
PHYSIOLOGY	functional connectivity, activation
STRUCTURE	
EPIGENETICS	Environmental influences
GENETICS	SNPs, microdeletions / microduplications,





Diagnostic journey of the vulnerable child

Stage	Diagnosis
Infancy	Infant distress / sleep dysregulation
Toddlerhood	Language delay
Pre-school	Aggression / social-emotional delay
Start of school	ADHD / ODD
Mid-primary school	Learning disorder
Mid-primary school	Autism spectrum disorder

Transitions


n Anticipated

- Commence school, high school

n Random

- birth sibling, family rearrangements (parental separation / re-partner), parental illness, grief,
- mismatch with new teacher

ADHD and adolescence



Long-term outcome




Increased risk

- ADHD - persistence / partial remission ~65% (*Greydanus 2007*)
- Academic failure / school drop-out (*Barbaresi 2007, Barkley 2006*)
- Smoking, alcohol, substance abuse
- Mental health problems eg. mood, ASPD
- (*Biederman, 1997; Elkins 2007; Farone, 2006; Secnik, 2005*)
- Unemployment / low occupational status / job retention (*Barkley 2006; Manuzza, 1993*)
- Injuries eg MCA (*Barkley 1996*)
- Delinquency / crime & incarceration
- Relationship difficulties
- Early parenthood / problems with parenting



Famous People with ADHD

- Albert Einstein
- Jim Carrey
- Vincent Van Gogh
- Stevie Wonder
- Michael Phelps



Assessment

- **History**
- **Examination**
- **Behaviour rating scales** (parent & teacher)
 - broad band eg Achenbach
 - ADHD specific eg Conners
- **Other professional assessments**
 - Psychology
 - cognitive, academic achievement
 - Speech pathology, occupational therapy, special education etc

Laboratory measures

- Neuropsychological tests
 - attention, memory, problem-solving, planning, processing speed
 - computerized tests of attention eg. TOVA, CPT
- Surface EEG - inc theta-beta ratio
- Quantitative EEG (brain mapping)
- fMRI
- PET, SPECT scanning

Differences in *group mean data*

Insufficient sensitivity and specificity for diagnosis

Differential diagnosis

- Normal
- Specific learning disorder
- Intellectual disability
- Emotional disturbance
 - adjustment reaction
 - attachment disorder / PTSD
 - anxiety/depression
- Personality disorders (adolescents / adults)
 - Borderline, narcissistic (disorganised, dysregulated)

Management

ALWAYS

- Behaviour modification
- Educational strategies
- **“Housekeeping”**

OFTEN

- **Medication**
- Talking therapies
 - individual
 - group
 - family

Housekeeping

- Comorbidities
 - learning disorders, anxiety, ASD
- Sleep
- Nutrition
 - macro, micro
- School
 - fit, bullying
- Seizures, general health

Professional services

- Paediatricians
 - make diagnosis in 73% (*Concannon et al JPCH 2005*)
 - prescribers of stimulants for 91% (*WA Dept Health 2007*)
- Psychology, child psychiatry, allied health, complementary practitioners
- Education – no extra support (*Efron et al Aust J Spec Ed 2008*)
- Adults – few services

Non-pharmacological interventions

(Sonuga-Barke Am J Psychiatry 2013)

	Effect size (ADHD symptoms)
Elimination diet	0.5
Exclude artificial colourings	0.3
FFA supplements	0.2
Cognitive training	0
Behavioural interventions / parent training	0
Neurofeedback	0

Behaviour modification

- Calmness
- Consistency
- Anticipate & avoid
- Lack internal locus of control
 - Praise and reward good behaviour
 - Ignore minor irritating behaviour
 - Immediate consequences for unacceptable behaviour
eg. time out, removal of privileges

Classroom adaptations

- Position in classroom
- Instructions
- Allow time, help pacing
- Breaks
- Frequent positive reinforcement
- Clear graded consequences

Medications in ADHD

- Stimulants
 - methylphenidate (Ritalin)
 - dexamphetamine
- Atomoxetine (Strattera)
- Clonidine (Catapres)

(Tricyclic antidepressants)

Psychostimulants

- dextroamphetamine - Bradley 1937 (post-LP headache)
- methylphenidate (*Ritalin*) 1956
- sympathomimetic
 - block re-uptake, ↑ pre-synaptic release, inhib MAO
 - ↑ DA and NA in synaptic cleft
- ↑ arousal & alertness

Stimulants: effects

- Improved vigilance / sustained attention
- Reduced impulsivity
- Reduced motor activity
- Increased compliance
- Improved parenting style
- Improved peer interactions / social standing

Stimulants effects


Cognitive

- Working memory / task planning
- Attention span / task completion

Academic

- Mental arithmetic
- Reading comprehension
- Handwriting
- Retention of new material

Stimulants – dose-response curve



Stimulants: side-effects

- **Anorexia → poor weight gains**
- **Emotional blunting (lose spark) – 5-10%?**
 - genotypic risk marker - COMT Met-Met?
- Anxiety
- Tics
- (Initial insomnia)
- Mild mean inc. HR, BP

Stimulants – risk sudden death?

- 2006 - alarm sans data (*Nissen NEJM*)
- Epidemiology – no incr. over background rate sudden unexplained death
- FDA recommendations:
 - History
 - child: syncope, dizziness, palpitations, SOB, chest pain
 - family: CVS disease, premature sudden death
 - Examination
 - If H +/-or E raise concern, or child develops symptoms
 - ECG, ECHO +/- cardiologist consult

Stimulant side-effects - long-term


- growth suppression
 - Possible small effect in sub-group
 - av 2cm less growth over 3 yrs
(MTA: Swanson JAACAP 2007)
- substance abuse
 - protective ?
 - Wilens *Pediatr* 2003 meta-analysis
 - Groenman et al *BJPsychiatry* 2013. 388 pts w ADHD, 327 treated with stimulants, 61 not. Mean age 16, retrospective f/up after 4 yrs, controlled for ODD, CD. Stimulant med reduced risk SUD by approx 2 (HR 1.1-3.4). No effect on nicotine use

Stimulants: long-term effects

- growth suppression
 - Possible small effect in sub-group
 - av 2cm less growth over 3 yrs
- substance abuse
 - no increase
 - protective ? (*Wilens 2003, Groenman 2013*)

Stimulant medication

(MTA Arch Gen Psychiatry 1999. $n = 579$)



- Longer term benefits uncertain – MTA 8 year follow-up (*Molina JAACAP 2009*) (messy data - assignment contaminated after 14 months etc)
 - no diff in symptoms or function
 - 60% initially assigned meds no longer taking – no diff in function



Methylphenidate

Duration

n	Ritalin 10	tablets	3-4 hrs
n	Ritalin LA	capsules	6-8 hrs
n	Concerta	long tablets	10-12 hrs

Ritalin LA


- caps with 50:50 immed:delayed- release MPH beads
- don't crush or chew; can open into soft food
- 10 / 20 / 30 /40 mg caps

Ritalin LA – in practice

- some delayed onset
- usually no dip
- usually as effective as IR MPH BD
- often wears off after 5-6 hours

CONCERTA

OROS Delivery System



Concerta (2003)

- Ascending profile (“acute tolerance”); 10-12 hrs
- 18 mg (5/5/5), 27mg (7.5), 36 mg (10), 54mg (15)
(USA have 72mg)
- = MPH IR TDS > placebo by teacher and parent ratings (Pelham et al Pediatrics 2001)

Stimulants: Troubleshooting

- Early emotional lability - persevere
- Rebound - 3.30 dose
- Wearing off early - extra dose
- Weight loss - post-meals, w/e “holidays”
- Insomnia - earlier, ↓ dose, pm dose, clonidine
- Dysphoria - alt. stimulant, ATX
- Tics
- Seizures

Practical tips

- Start 7 days
- Don't over-attribute
- Always assume non-compliance
- Document scripts written
 - calculate time tabs will last

Stimulant use in Australia

- Nationally: 1% boys, 0.5% girls (*Salmelainen 2002; Hollingworth ANZ J Psychiatry 2011*)
- Rates vary by state, region
- 81% children with ADHD (*Efron 2013*)
 - Predicted by age (peak adolescence); not SES, gender, comorbidity

Atomoxetine (Strattera)

- selective noradrenaline reuptake inhibitor
- once/d - steady state effect
- **takes up to 8 weeks for full effect**
- smaller effect size than stimulants
- few SEs - can be sedating
- some anti-anxiety and anti-tic effects

Clonidine

- n α_2 adrenergic agonist
 - widely distributed in brain
 - implicated in pathophysiology of disruptive behaviour disorders
- n psychoactive properties via NA, 5-HT and DA systems $\therefore$ interest in application to many psych syndromes (Tourette, BAD, SCZ, PTSD, social phobias, panic disorder, BZD w/d)

Clonidine in ADHD

- moderate positive effect size (variable)

(Meta-analysis: *Connor JAACAP 1999*)

- recommend 2nd line
- Added to stimulants - reduces ODD / CD symptoms
(*Hazell JAACAP 2003*)
- some decr. tics
- AEs: sedation, irritability

Safe use of clonidine

- **Store safely**
- HR, BP (incl postural drop)
 - baseline and monitor
- lowest possible dose - < 200mcg/d
- use BD in combination with MPH
- taper slowly (rebound hypertension)

Antidepressants

- **SSRIs**
 - for comorbid anxiety
- **Tricyclics** (amitriptyline, imipramine, desipramine)
 - if comorbid anxiety, depression
 - baseline ECG if $> 2\text{mg/kg/day}$
 - anticholinergics AEs
- **Moclobemide, SNRIs**

Predictors of outcome - intuition

- Age of onset / Severity
- Subtype
- Comorbidities
- Age of diagnosis / intervention
- Type / quality of intervention
- Parental psychopathology

PATHWAYS / TRAJECTORIES

Longitudinal studies in ADHD: Problems

- Clinical samples
- Poorly characterised samples (especially comorbidities)
- Wide age-range at recruitment
- Infrequent measurement
- Few included inattentives
- Most Nth American

Research gaps

- Continuity of EF deficits (attention, WM)
- Stability of caseness
- Gender comparisons
- Predictors of better / worse outcomes
 - **modifiable risk factors**
 - Influence of interventions on long-term outcomes

Developmental trajectories:

Diagnostic journey of the vulnerable child

- Infant distress / sleep / feeding disorder
- Language delay
- Pre-school aggression
- Social-emotional delay
- ADHD-Combined type
- Learning disability
- Oppositional defiant disorder
- High functioning autism
- Generalised anxiety disorder
- Depression
- Substance use disorder

Developmental trajectories

n “Emergence”

- transition of degree rather than kind
- precipitated by enviro challenges
- early (temperamental / dev delay in emotional regulation & impulse control)
 - vs late
 - prognostic significance unknown
 - most identified in middle childhood

n Persistence

n “Remission” (partial)

n “Relapse”

Causal pathways: Principles Of Developmental (Psycho)pathology

Aetiological heterogeneity

- Multiple risk-factors
 - some fixed, some modifiable
 - a continuum of neurobiological risk in population
- Individual effect sizes small
- Dynamic interactions
 - incl. with individual child (non-ADHD) factors
 - moderating factors can alter trajectories
- Critical windows

Clinical phenotype is dynamic

- fluctuation in symptom expression, & assoc impairment, day-day, year-year (real?)

Causal pathways: Principles Of Developmental (Psycho)pathology (cont.)

- Different subgroups follow different pathways
- Equifinality - diff risks → same outcomes
- Multifinality – same pattern RFs → diff outcomes
- Dimensionality
 - “casesness” is arbitrary
- Neuroplasticity (*eg. prevention of autism Dawson 2008*)

Causal pathways

(Nigg 2006, Sonuga-Barke 2010)

VISION

Identify:

- Early developmental phenotypes
- Mediating processes (dynamic)
 - targets for early intervention

Goals:

- reduce likelihood emergence
- limit persistence
- increase likelihood remission
- reduce long-term burdens

Early intervention

- Primary (prevention) - not feasible; predictive power of risk markers not strong enough
- **Secondary** (early phenotypic indicators eg. family Hx / RFs / hyperactivity / dysregulation) – potential
- Tertiary (early tx of disorder) – pharmacol, non-pharmacol
 - no evidence of alteration to dev trajectories

Interventions which might alter developmental trajectories

- n Parent support & training (*Shaw 2008*)
 - Eg. Triple P (*Sanders*), Incredible Years (*Webster-Stratton*)
 - Evidence red. levels oppositionality / conduct problems
- n Neuropsychological (speed rate of dev)
 - Attention training (*Sohlberh & Mateer 2001*)
 - Working memory training (*Klingberg et al 2005*)
 - Improvements in lab performance demonstrated - ? transferrable to classroom / playground / home; sustained?
- n Operant conditioning
- n Combination
 - homework exercises to improve self-regulation
 - Games: conc, turn-taking, delay gratification
 - “Teachable moments”
 - parents agents of change